Anti-Hypertensive Drugs - Southeast Asia

Southeast Asia

Highlights

The Anti-Hypertensive Drugs market in Southeast Asia is forecasted to achieve a revenue of US$245.90m by the year 2024.
With an anticipated annual growth rate (CAGR 2024-2029) of 0.63%, the market volume is projected to reach US$253.80m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$12.29bn in 2024.
In Southeast Asia, there is a growing demand for anti-hypertensive drugs due to the increasing prevalence of hypertension in the region.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for anti-hypertensive drugs has been growing steadily in Southeast Asia, driven by a combination of factors such as an aging population, changing lifestyles, and increasing awareness of hypertension as a major health issue.

Customer preferences: Patients in Southeast Asia are increasingly seeking out more convenient and affordable treatment options for hypertension. This has led to a rise in demand for generic drugs and fixed-dose combination therapies that offer a more cost-effective and simplified approach to treatment. Additionally, patients are showing a preference for drugs that have fewer side effects and are easier to administer.

Trends in the market: The anti-hypertensive drugs market in Southeast Asia is expected to continue to grow over the next few years, driven by factors such as rising healthcare expenditure, increasing prevalence of hypertension, and the introduction of new and innovative drugs. However, the market is also facing challenges such as increasing competition from generic drugs, regulatory hurdles, and a lack of awareness and education among patients and healthcare providers.In Indonesia, for example, the market is expected to grow due to the country's large population and rising middle class, which is driving demand for better healthcare services. In Thailand, the market is being driven by the government's efforts to promote healthy lifestyles and prevent chronic diseases such as hypertension. Meanwhile, in Vietnam, the market is being driven by the increasing prevalence of hypertension among the population, particularly among the elderly.

Local special circumstances: One of the key challenges facing the anti-hypertensive drugs market in Southeast Asia is the lack of access to healthcare services in many parts of the region. This is particularly true in rural areas, where there is often a shortage of healthcare providers and facilities. In addition, there is a lack of awareness and education among patients and healthcare providers about the importance of hypertension management, which can lead to underdiagnosis and undertreatment of the condition.

Underlying macroeconomic factors: The anti-hypertensive drugs market in Southeast Asia is also being influenced by broader macroeconomic factors such as population growth, urbanization, and increasing healthcare expenditure. As the population in the region continues to grow and urbanize, there is likely to be an increasing demand for healthcare services and pharmaceutical products. At the same time, governments in the region are investing more in healthcare infrastructure and services, which is likely to support the growth of the anti-hypertensive drugs market in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.